InsidersTradesSigma
Total declarations
Company
▲ Purchases (6 ops.)
▼ Sales (0 ops.)
Discover the detailed record of transactions filed by Debbink Dirk J, Chairman & CEO. Director active across 1 companies, notably Cincinnati Financial CORP. In total, 8 filings have been published. Total volume traded: €353k. The latest transaction was filed on 20 May 2022 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Declarations8 total
€46,766410 shares@ €114.06290.0002% mcap13.3% of flow
Common Stock
SEC:0001562180-22-004359:0·
Ideal exit: 14 Feb 2023 (T+270)
€44,376400 shares@ €110.93970.0002% mcap12.6% of flow
Common Stock
SEC:0001562180-22-002388:0·
Ideal exit: 28 Nov 2022 (T+270)
0867 shares0
Common Stock
SEC:0001562180-22-000784·
0867 shares0
Common Stock
SEC:0001562180-22-000784:0·
€88,436855 shares@ €103.43440.0003% mcap67.6% of flow
Common Stock
SEC:0001562180-21-007356·
Ideal exit: 26 Aug 2022 (T+270)
€88,436855 shares@ €103.43440.0003% mcap25.1% of flow
Common Stock
SEC:0001562180-21-007356:0·
Ideal exit: 26 Aug 2022 (T+270)
€42,381419 shares@ €101.14780.0002% mcap32.4% of flow
Common Stock
SEC:0001562180-21-005283·
Ideal exit: 6 May 2022 (T+270)
€42,381419 shares@ €101.14780.0002% mcap12.0% of flow
Common Stock
SEC:0001562180-21-005283:0·
Ideal exit: 6 May 2022 (T+270)
8 of 8 declarations
About Debbink Dirk J
Dan Yrigoyen is the Chief Executive Officer and Vice President of Sales at Arch Therapeutics, Inc. In this role, he oversees the operations and strategy of the company, focusing on sales growth and innovation. Dan is responsible for strategic direction and customer relationship management, playing a key role in the company's development.
